# A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

> **NCT00532155** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 913 (actual)

## Conditions studied

- Carcinoma
- Non Small Cell Lung

## Interventions

- **DRUG:** Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- **DRUG:** Placebo
- **DRUG:** Docetaxel (Taxotere®)
- **DRUG:** Dexamethasone (pre- and post-medication for docetaxel)

## Key facts

- **NCT ID:** NCT00532155
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2011-01
- **Final completion:** 2011-10
- **Target enrollment:** 913 (ACTUAL)
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532155, "A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00532155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*